Management of Philadelphia chromosome-positive acute lymphoblastic leukemiaOTTMANN, O. G.Leukemia supplements (Print). 2012, Vol 1, Num 2, issn 2044-5210, S7-S9Conference Paper

Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia ?OTTMANN, O. G; HOELZER, D.Leukemia. 1996, Vol 10, Num 7, pp 1111-1116, issn 0887-6924Article

Differential proliferative effects of transforming growth factor-β on human hematopoietic progenitor cellsOTTMANN, O. G; PELUS, L. M.The Journal of immunology (1950). 1988, Vol 140, Num 8, pp 2661-2665, issn 0022-1767Article

Megakaryocytic growth factors : is there a new approach for management of thrombocytopenia in patients with malignancies?HOFMANN, W. K; OTTMANN, O. G; HOELZER, D et al.Leukemia. 1999, Vol 13, Num 1, pp 14-18, issn 0887-6924Article

Interleukin 3 and interleukin 3/GM-CSF combination therapy ― clinical implicationsGANSER, A; OTTMANN, O. G; HOELZER, D et al.Stem cells (Dayton, OH). 1993, Vol 11, Num 6, pp 465-473, issn 1066-5099Article

Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-α, -β, and -γ and an effect mediated by tumor necrosis factorPELUS, L. M; OTTMANN, O. G; NOCKA, K. H et al.The Journal of immunology (1950). 1988, Vol 140, Num 2, pp 479-484, issn 0022-1767Article

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparationsPURSCHE, S; OTTMANN, O. G; EHNINGER, G et al.Journal of chromatography. B. 2007, Vol 852, Num 1-2, pp 208-216, issn 1570-0232, 9 p.Article

Acute lymphoblastic leukemia with the (4;11) translocation : combined cytogenetic, immunological and molecular genetic analysesSCHARDT, C; OTTMANN, O. G; HOELZER, D et al.Leukemia. 1992, Vol 6, Num 5, pp 370-374, issn 0887-6924Article

Simultaneous production of tumor necrosis factor-α and lymphotoxin by normal T cells after induction with IL-2 and anti-T3STEFFEN, M; OTTMANN, O. G; MOORE, M. A. S et al.The Journal of immunology (1950). 1988, Vol 140, Num 8, pp 2621-2624, issn 0022-1767Article

Kleine-Levin and Munchausen syndromes in a patient with recurrent acromegalyJUNGHEIM, K; BADENHOOP, K; OTTMANN, O. G et al.European journal of endocrinology. 1999, Vol 140, Num 2, pp 140-142, issn 0804-4643Article

Growth factors in the treatment of acute lymphoblastic leukemiaOTTMANN, O. G; HOELZER, D.Leukemia research. 1998, Vol 22, Num 12, pp 1171-1178, issn 0145-2126Article

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABLMIAN, A. A; OANCEA, C; ZHAO, Z et al.Leukemia. 2009, Vol 23, Num 12, pp 2242-2247, issn 0887-6924, 6 p.Article

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance developmentBURCHERT, A; WANG, Y; CAI, D et al.Leukemia. 2005, Vol 19, Num 10, pp 1774-1782, issn 0887-6924, 9 p.Article

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. CommentaryOLAVARRIA, E; OTTMANN, O. G; ULLMANN, A et al.Leukemia. 2003, Vol 17, Num 9, pp 1707-1712, issn 0887-6924, 6 p., 1722 [7 p.]Article

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)WASSMANN, B; PFEIFER, H; SCHEURING, U et al.Leukemia. 2002, Vol 16, Num 12, pp 2358-2365, issn 0887-6924, 8 p.Article

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicinSEIPELT, G; HOFMANN, W.-K; MARTIN, H et al.Annals of hematology (Print). 1998, Vol 76, Num 3-4, pp 145-151, issn 0939-5555Article

Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein bindingSTRATMANN, G; HARDER, S; HÖLZER, D et al.International journal of clinical pharmacology and therapeutics. 1998, Vol 36, Num 2, pp 103-106, issn 0946-1965Conference Paper

Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromesGANSER, A; OTTMANN, O. G; HOELZER, D et al.Leukemia. 1993, Vol 7, Num 5, pp 696-701, issn 0887-6924Article

Myelokathexis treated with recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)HESS, U; GANSER, A; SCHNÜRCH, H.-G et al.British journal of haematology. 1992, Vol 80, Num 2, pp 254-256, issn 0007-1048Article

Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vitroOTTMANN, O. G; GANSER, A; SEIPELT, A et al.Blood. 1990, Vol 76, Num 8, pp 1494-1502, issn 0006-4971Article

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantationWASSMANN, B; KLEIN, S. A; SCHEURING, U et al.Bone marrow transplantation (Basingstoke). 2001, Vol 28, Num 7, pp 721-724, issn 0268-3369Article

Assignment of the human histone deacetylase 6 gene (HDAC6) to X chromosome p11.23 by in situ hybridizationMAHLKNECHT, U; SCHNITTGER, S; LANDGRAF, F et al.Cytogenetics and cell genetics. 2001, Vol 93, Num 1-2, pp 135-136, issn 0301-0171Article

BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activityPUCCETTI, E; GÜLLER, S; ORLETH, A et al.Cancer research (Baltimore). 2000, Vol 60, Num 13, pp 3409-3413, issn 0008-5472Article

Myelodysplastic syndromes : Clinical featuresHOFMANN, W. K; OTTMANN, O. G; GANSER, A et al.Seminars in hematology. 1996, Vol 33, Num 3, pp 177-185, issn 0037-1963Article

In vitro culture of common acute lypmphoblastic leukemia blast : effects of interleukin-3, interleukin-7, and accessory cellsEDER, M; OTTMANN, O. G; HANSEN-HAGGE, T. E et al.Blood. 1992, Vol 79, Num 12, pp 3274-3284, issn 0006-4971Article